Emerging Technology Reports

The Emerging Technology Report provides regular updates about emerging and potentially disruptive technologies that are likely to have a significant impact in healthcare. This “early warning” report monitors new health technologies from 6 months to 2 years within a regulatory submission and tracks those as they go through clinical trial development and the regulatory approval process.

For each emerging technology, our analysts describe the technology and intended use, its prospects relative to the regulatory process and FDA information, competing technologies, relevant clinical guidelines, high-level look at the evidence such as published abstracts in the medical literature and available meeting abstracts, and available clinical trials.

Laquinimod

An oral immunomodulator for the treatment of relapsing remitting multiple sclerosis.

Ion™ Stent for Acute Myocardial Infarction

A paclitaxel-eluting, platinum chromium alloy stent intended for use in patients undergoing primary angioplasty to treat acute ST-segment elevation myocardial infarction.

Raven Mobile Surgical Robot

A mobile, lightweight, modular robotic surgical system designed to perform telesurgery over long distances.  

Kalydeco™ (VX-770, Ivacaftor)

An oral cystic fibrosis transmembrane regulator potentiator for the treatment of cystic fibrosis in patients aged 6 years or older who have the rare G551D variant in the CFTR gene.

NanoKnife® System

A minimally invasive system that uses irreversible electroporation for surgical ablation of soft tissue.